You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Beckman Coulter announced changes to its board, Steven Salzberg moves to Johns Hopkins, Complete Genomics names a new senior vice president and chief commercial officer, and more.
The tender offer period finished with around 92 percent of Beckman Coulter shareholders tendering their shares.
Danaher commenced a subsequent offering period set to expire on June 29, after which it expects to complete its purchase of Beckman Coulter.
The European Commission approved the deal, clearing the way for Danaher to complete the $6.8 billion purchase by the end of the month.
President and CEO J. Robert Hurley is now also interim Diagnostic Division President, while Scott Atkins was named president of the Life Science Division.
The company said that it anticipates regulatory approval from the European Commission on or about June 16 and to close the acquisition by the end of the month.
The company's Clinical Diagnostics segment was up 3 percent year over year, while Life Science slid 11 percent.
The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.
The deadline for the deal has been pushed back to April 27 from March 23.
In a research note, Jon Groberg wrote that in the near term firms with a larger consumables presence in Japan face greater revenue risk, while instrument firms face greater mid-term risk.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.